Study reveals NovoEight retains potency at temperatures as high as 40°c

A long-term study has shown that NovoEight (turoctocog alfa) remains effective after three months of storage at a temperature of 40°c (104°f), according to findings presented on Monday at the World Federation of Hemophilia.

The findings have the potential to improve the quality of life of hemophilia A sufferers living in warmer climates, as until this point the storage requirements of treatments have served as an impediment to patients travelling, participating in sports or engaging in other physical activities.

“Establishing the stability of NovoEight up to 40° is part of our commitment to helping people with hemophilia A to reduce the burden that this condition places on their lives,” said Mads Krogsgaard Thomsen, ‎executive vice president and chief science officer at Novo Nordisk (NOV: N), which markets the drug.